Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Linkinvax Raises €4.350 Million In Funding
PRIVATEFeb 10, 2022•over 4 years ago
Amount Raised
€4.35 Million
Round Type
Seed
Paris
Description
LinKinVax, a clinical-stage biotechnology company is announcing completion of a €4.350 million seed capital funding round. It was led by LinKinVax’s core shareholders and business angels and will enable LinKinVax to accelerate the clinical development of its innovative protein-based vaccine platform, which can be tweaked to changes and mutations in target pathogens.
Company Information
Company
Lin Kin Vax Technology
Location
Paris, Ile De France, France
About
LinKinVax’s vaccine platform is built around a humanized monoclonal antibody, which is merged with regions of pathogens of interest, targeting the CD40 molecule expressed by dendritic cells, DC, which play a key role in stimulating the immune system. The results obtained demonstrate the benefits of this strategy owing to the small quantity of antigens required to activate the immune system, with or without an adjuvant, and its ability to trigger a lasting cellular and humoral and immune response. The platform also benefits from the experience and safety profile of the protein-based vaccines that have been widely used for over 30 years now.
Three products are in or about to enter clinical trials: a prophylactic vaccine for HIV, currently in phase I led by Inserm/ANRS-EID), a SARS-CoV-2 vaccine covering variants of interest, and a therapeutic vaccine for human papillomavirus-related cancers.
Don't miss Lin Kin Vax Technology's next move
Get an email the moment Lin Kin Vax Technology raises, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Predictive Intelligence
Strategic
ML-powered predictions for Lin Kin Vax Technology's next move
Paris